Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D., Lyndal Harborne, B.Med., David T. MacLaughlin, Ph.D., Daniel Ling, Jane Norman, M.D., Naveed Sattar, M.R.C.Path., David B. Seifer, M.D. Fertility and Sterility Volume 83, Issue 1, Pages 130-136 (January 2005) DOI: 10.1016/j.fertnstert.2004.05.098 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions
FIGURE 1 The changes in the mean concentrations of A and MIS during metformin treatment of women with PCOS. The significance values refer to changes between the start of treatment (T0) and at 4 months as well as between the 4- and 8-month intervals. Fertility and Sterility 2005 83, 130-136DOI: (10.1016/j.fertnstert.2004.05.098) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions